BIOMARKER:

EGFR exon 19 mutation

B | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

B | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

Non Small Cell Lung Cancer

Lung Adenocarcinoma

Pancreatic Adenocarcinoma

Small Cell Lung Cancer

erlotinib + ramucirumab

EGFR exon 19 mutation|Non Small Cell Lung Cancer|erlotinib + ramucirumab

icotinib

EGFR exon 19 mutation|Non Small Cell Lung Cancer|icotinib

erlotinib

EGFR exon 19 mutation|Non Small Cell Lung Cancer|erlotinib

EGFR exon 19 mutation|Lung Adenocarcinoma|erlotinib

EGFR exon 19 mutation|Pancreatic Adenocarcinoma|erlotinib

osimertinib

EGFR exon 19 mutation|Non Small Cell Lung Cancer|osimertinib

EGFR exon 19 mutation|Lung Adenocarcinoma|osimertinib

EGFR exon 19 mutation|Small Cell Lung Cancer|osimertinib

afatinib

EGFR exon 19 mutation|Non Small Cell Lung Cancer|afatinib

bevacizumab + erlotinib

EGFR exon 19 mutation|Lung Adenocarcinoma|bevacizumab + erlotinib

gefitinib

EGFR exon 19 mutation|Non Small Cell Lung Cancer|gefitinib

FCN-411

EGFR exon 19 mutation|Non Small Cell Lung Cancer|FCN-411

cisplatin + gefitinib + docetaxel

EGFR exon 19 mutation|Non Small Cell Lung Cancer|cisplatin + gefitinib + docetaxel

Immunotherapy

EGFR exon 19 mutation|Non Small Cell Lung Cancer|Immunotherapy